Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Giorgio Parmiani

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Procedures

Concepts & Ideas

Molecular Sequence Data

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Daniotti Maria; Ferrari Andrea; Frigerio Simona; Casieri Paola; Miselli Francesca; Zucca Elisa; Collini Paola; Della Torre Gabriella; Manoukian Siranoush; Peissel Bernard; Bono Aldo; Santinami Mario; Parmiani Giorgio; Rivoltini Licia; Pilotti Silvana; Rodolfo Monica
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
Iero Manuela; Filipazzi Paola; Castelli Chiara; Belli Filiberto; Valdagni Riccardo; Parmiani Giorgio; Patuzzo Roberto; Santinami Mario; Rivoltini Licia
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
Maccalli Cristina; Scaramuzza Samantha; Parmiani Giorgio
TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Giorgio Parmiani (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Daniotti Maria; Ferrari Andrea; Frigerio Simona; Casieri Paola; Miselli Francesca; Zucca Elisa; Collini Paola; Della Torre Gabriella; Manoukian Siranoush; Peissel Bernard; Bono Aldo; Santinami Mario; Parmiani Giorgio; Rivoltini Licia; Pilotti Silvana; Rodolfo Monica
Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT.
The Journal of investigative dermatology 2009;129(7):1759-68.
2009: Iero Manuela; Filipazzi Paola; Castelli Chiara; Belli Filiberto; Valdagni Riccardo; Parmiani Giorgio; Patuzzo Roberto; Santinami Mario; Rivoltini Licia
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
Cancer immunology, immunotherapy : CII 2009;58(7):1159-67.
2009: Maccalli Cristina; Scaramuzza Samantha; Parmiani Giorgio
TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Cancer immunology, immunotherapy : CII 2009;58(5):801-8.
2009: Tassi Elena; Braga Marco; Longhi Renato; Gavazzi Francesca; Parmiani Giorgio; Di Carlo Valerio; Protti Maria Pia
Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients.
PloS one 2009;4(10):e7234.
2008: Maccalli Cristina; Di Cristanziano Veronica; Fodale Valentina; Corsi Domenico; D'Agostino Giuseppina; Petrangeli Valentina; Laurenti Luca; Guida Sofia; Mazzocchi Arabella; Arienti Flavio; Perrone Maria P; Castelli Chiara; Rivoltini Licia; Zagonel Vittorina; Tartaglia Marco; Parmiani Giorgio; Belardelli Filippo
Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7292-303.
2008: De Filippo AnnaMaria; Binder Robert J; Camisaschi Chiara; Beretta Valeria; Arienti Flavio; Villa Antonello; Della Mina Pamela; Parmiani Giorgio; Rivoltini Licia; Castelli Chiara
Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses.
Journal of immunology (Baltimore, Md. : 1950) 2008;181(9):6525-35.
2008: Vezzoni Luca; Parmiani Giorgio
Limitations of the cancer stem cell theory.
Cytotechnology 2008;58(1):3-9.
2008: Novellino Luisa; De Filippo Annamaria; Deho Paola; Perrone Federica; Pilotti Silvana; Parmiani Giorgio; Castelli Chiara
PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells.
Cellular signalling 2008;20(5):872-83.
2008: Maio Michele; Fonsatti Ester; Burigo Arianna; Parmiani Giorgio
The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level.
Tumori 2008;94(2):179-81.
2008: Casati Chiara; Camisaschi Chiara; Novellino Luisa; Mazzocchi Arabella; Triebel Frédéric; Rivoltini Licia; Parmiani Giorgio; Castelli Chiara
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(6):3782-8.
2008: Vallacchi Viviana; Daniotti Maria; Ratti Francesca; Di Stasi Delia; Deho Paola; De Filippo Annamaria; Tragni Gabrina; Balsari Andrea; Carbone Antonino; Rivoltini Licia; Parmiani Giorgio; Lazar Noureddine; Perbal Bernard; Rodolfo Monica
CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma.
Cancer research 2008;68(3):715-23.
2008: Iero M; Valenti R; Huber V; Filipazzi P; Parmiani G; Fais S; Rivoltini L
Tumour-released exosomes and their implications in cancer immunity.
Cell death and differentiation 2008;15(1):80-8.
2008: Maio Michele; Nicolay Hugues Jm; Ascierto Paolo; Belardelli Filippo; Camerini Roberto; Colombo Mario P; Queirolo Paola; Ridolfi Ruggero; Russo Vincenzo; Anzalone Lucia; Fonsatti Ester; Parmiani Giorgio
The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.
Journal of translational medicine 2008;6():8.
2007: Maccalli Cristina; Nonaka Daisuke; Piris Adriano; Pende Daniela; Rivoltini Licia; Castelli Chiara; Parmiani Giorgio
NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7459-68.
2007: Iero Manuela; Squarcina Paola; Romero Pedro; Guillaume Philippe; Scarselli Elisa; Cerino Raffaele; Carrabba Matteo; Toutirais Olivier; Parmiani Giorgio; Rivoltini Licia
Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptide.
Cancer immunology, immunotherapy : CII 2007;56(12):1979-91.
2007: Parmiani Giorgio; Russo Vincenzo; Marrari Andrea; Cutolo Gianluca; Casati Chiara; Pilla Lorenzo; Maccalli Cristina; Rivoltini Licia; Castelli Chiara
Universal and stemness-related tumor antigens: potential use in cancer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(19):5675-9.
2007: Del Vecchio Michele; Bajetta Emilio; Canova Stefania; Lotze Michael T; Wesa Amy; Parmiani Giorgio; Anichini Andrea
Interleukin-12: biological properties and clinical application.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(16):4677-85.
2007: Filipazzi Paola; Valenti Roberta; Huber Veronica; Pilla Lorenzo; Canese Paola; Iero Manuela; Castelli Chiara; Mariani Luigi; Parmiani Giorgio; Rivoltini Licia
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(18):2546-53.
2007: Dalerba Piero; Dylla Scott J; Park In-Kyung; Liu Rui; Wang Xinhao; Cho Robert W; Hoey Timothy; Gurney Austin; Huang Emina H; Simeone Diane M; Shelton Andrew A; Parmiani Giorgio; Castelli Chiara; Clarke Michael F
Phenotypic characterization of human colorectal cancer stem cells.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(24):10158-63.
2007: Daniotti Maria; Vallacchi Viviana; Rivoltini Licia; Patuzzo Roberto; Santinami Mario; Arienti Flavio; Cutolo Gianluca; Pierotti Marco A; Parmiani Giorgio; Rodolfo Monica
Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.
International journal of cancer. Journal international du cancer 2007;120(11):2439-44.
2007: Valenti Roberta; Huber Veronica; Iero Manuela; Filipazzi Paola; Parmiani Giorgio; Rivoltini Licia
Tumor-released microvesicles as vehicles of immunosuppression.
Cancer research 2007;67(7):2912-5.
2007: Ferrantini Maria; Capone Imerio; Marincola Francesco M; Parmiani Giorgio; Belardelli Filippo
International meeting "Immunotherapy of cancer: challenges and needs".
Cancer immunology, immunotherapy : CII 2007;56(4):581-5.
2007: Marrari Andrea; Iero Manuela; Pilla Lorenzo; Villa Sergio; Salvioni Roberto; Valdagni Riccardo; Parmiani Giorgio; Rivoltini Licia
Vaccination therapy in prostate cancer.
Cancer immunology, immunotherapy : CII 2007;56(4):429-45.
2007: Parmiani Giorgio; Castelli Chiara; Santinami Mario; Rivoltini Licia
Melanoma immunology: past, present and future.
Current opinion in oncology 2007;19(2):121-7.
2007: Parmiani Giorgio; De Filippo Annamaria; Novellino Luisa; Castelli Chiara
Unique human tumor antigens: immunobiology and use in clinical trials.
Journal of immunology (Baltimore, Md. : 1950) 2007;178(4):1975-9.
2007: Parmiani G; Castelli C; Pilla L; Santinami M; Colombo M P; Rivoltini L
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(2):226-32.
2006: Valenti Roberta; Huber Veronica; Filipazzi Paola; Pilla Lorenzo; Sovena Gloria; Villa Antonello; Corbelli Alessandro; Fais Stefano; Parmiani Giorgio; Rivoltini Licia
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
Cancer research 2006;66(18):9290-8.
2006: Pilla Lorenzo; Valenti Roberta; Marrari Andrea; Patuzzo Roberto; Santinami Mario; Parmiani Giorgio; Rivoltini Licia
Vaccination: role in metastatic melanoma.
Expert review of anticancer therapy 2006;6(8):1305-18.
2006: Pilla Lorenzo; Patuzzo Roberto; Rivoltini Licia; Maio Michele; Pennacchioli Elisabetta; Lamaj Elda; Maurichi Andrea; Massarut Samuele; Marchianò Alfonso; Santantonio Cristina; Tosi Diego; Arienti Flavio; Cova Agata; Sovena Gloria; Piris Adriano; Nonaka Daisuke; Bersani Ilaria; Di Florio Annabella; Luigi Mariani; Srivastava Pramod K; Hoos Axel; Santinami Mario; Parmiani Giorgio
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Cancer immunology, immunotherapy : CII 2006;55(8):958-68.
2006: Sensi M; Nicolini G; Petti C; Bersani I; Lozupone F; Molla A; Vegetti C; Nonaka D; Mortarini R; Parmiani G; Fais S; Anichini A
Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.
Oncogene 2006;25(24):3357-64.
2006: Parmiani Giorgio; De Filippo Annamaria; Pilla Lorenzo; Castelli Chiara; Rivoltini Licia
Heat shock proteins gp96 as immunogens in cancer patients.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2006;22(3):223-7.
2006: Di Pucchio Tiziana; Pilla Lorenzo; Capone Imerio; Ferrantini Maria; Montefiore Enrica; Urbani Francesca; Patuzzo Roberto; Pennacchioli Elisabetta; Santinami Mario; Cova Agata; Sovena Gloria; Arienti Flavio; Lombardo Claudia; Lombardi Arianna; Caporaso Patrizia; D'Atri Stefania; Marchetti Paolo; Bonmassar Enzo; Parmiani Giorgio; Belardelli Filippo; Rivoltini Licia
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Cancer research 2006;66(9):4943-51.
2006: Casati Chiara; Camisaschi Chiara; Rini Francesca; Arienti Flavio; Rivoltini Licia; Triebel Frédéric; Parmiani Giorgio; Castelli Chiara
Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.
Cancer research 2006;66(8):4450-60.
2006: Lugini Luana; Matarrese Paola; Tinari Antonella; Lozupone Francesco; Federici Cristina; Iessi Elisabetta; Gentile Massimo; Luciani Francesca; Parmiani Giorgio; Rivoltini Licia; Malorni Walter; Fais Stefano
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells.
Cancer research 2006;66(7):3629-38.
2005: Parmiani Giorgio
Tumor-infiltrating T cells--friend or foe of neoplastic cells?
The New England journal of medicine 2005;353(25):2640-1.
2005: Rodolfo Monica; Pierotti Marco A; Parmiani Giorgio
A merging duo in melanoma formation.
The Journal of investigative dermatology 2005;125(6):xii-xiii.
2005: Huber Veronica; Fais Stefano; Iero Manuela; Lugini Luana; Canese Paola; Squarcina Paola; Zaccheddu Annamaria; Colone Marisa; Arancia Giuseppe; Gentile Massimo; Seregni Ettore; Valenti Roberta; Ballabio Giuseppina; Belli Filiberto; Leo Ermanno; Parmiani Giorgio; Rivoltini Licia
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.
Gastroenterology 2005;128(7):1796-804.
2005: Pilla Lorenzo; Squarcina Paola; Coppa Jorgelina; Mazzaferro Vincenzo; Huber Veronica; Pende Daniela; Maccalli Cristina; Sovena Gloria; Mariani Luigi; Castelli Chiara; Parmiani Giorgio; Rivoltini Licia
Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96.
Cancer research 2005;65(9):3942-9.
2005: Rivoltini Licia; Canese Paola; Huber Veronica; Iero Manuela; Pilla Lorenzo; Valenti Roberta; Fais Stefano; Lozupone Francesco; Casati Chiara; Castelli Chiara; Parmiani Giorgio
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?
Expert opinion on biological therapy 2005;5(4):463-76.
2005: Dalerba Piero; Guiducci Cristiana; Poliani Pietro Luigi; Cifola Ingrid; Parenza Mariella; Frattini Milo; Gallino Gianfrancesco; Carnevali Ileana; Di Giulio Ilvia; Andreola Salvatore; Lombardo Claudia; Rivoltini Licia; Schweighoffer Tamás; Belli Filiberto; Colombo Mario P; Parmiani Giorgio; Castelli Chiara
Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells.
Cancer research 2005;65(6):2321-9.
2005: Novellino Luisa; Castelli Chiara; Parmiani Giorgio
A listing of human tumor antigens recognized by T cells: March 2004 update.
Cancer immunology, immunotherapy : CII 2005;54(3):187-207.
2005: Sensi Marialuisa; Nicolini Gabriella; Zanon Marina; Colombo Chiara; Molla Alessandra; Bersani Ilaria; Lupetti Raffaella; Parmiani Giorgio; Anichini Andrea
Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
Cancer research 2005;65(2):632-40.
2004: Parmiani Giorgio; Testori Alessandro; Maio Michele; Castelli Chiara; Rivoltini Licia; Pilla Lorenzo; Belli Filiberto; Mazzaferro Vincenzo; Coppa Jorgelina; Patuzzo Roberto; Sertoli Mario R; Hoos Axel; Srivastava Pramod K; Santinami Mario
Heat shock proteins and their use as anticancer vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8142-6.
2004: Luciani Francesca; Spada Massimo; De Milito Angelo; Molinari Agnese; Rivoltini Licia; Montinaro Annalisa; Marra Manuela; Lugini Luana; Logozzi Mariantonia; Lozupone Francesco; Federici Cristina; Iessi Elisabetta; Parmiani Giorgio; Arancia Giuseppe; Belardelli Filippo; Fais Stefano
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Journal of the National Cancer Institute 2004;96(22):1702-13.
2004: Belardelli Filippo; Ferrantini Maria; Parmiani Giorgio; Schlom Jeffrey; Garaci Enrico
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
Cancer research 2004;64(18):6827-30.
2004: Di Nicola Massimo; Carlo-Stella Carmelo; Mortarini Roberta; Baldassari Paola; Guidetti Anna; Gallino Gian Francesco; Del Vecchio Michele; Ravagnani Fernando; Magni Michele; Chaplin Paul; Cascinelli Natale; Parmiani Giorgio; Gianni Alessandro M; Anichini Andrea
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5381-90.
2004: Daniotti Maria; Oggionni Maria; Ranzani Tiziana; Vallacchi Viviana; Campi Valentina; Di Stasi Delia; Torre Gabriella Della; Perrone Federica; Luoni Chiara; Suardi Simona; Frattini Milo; Pilotti Silvana; Anichini Andrea; Tragni Gabrina; Parmiani Giorgio; Pierotti Marco A; Rodolfo Monica
BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Oncogene 2004;23(35):5968-77.
2004: Tosi Diego; Valenti Roberta; Cova Agata; Sovena Gloria; Huber Veronica; Pilla Lorenzo; Arienti Flavio; Belardelli Filippo; Parmiani Giorgio; Rivoltini Licia
Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(9):5363-70.
2004: Castelli Chiara; Rivoltini Licia; Rini Francesca; Belli Filiberto; Testori Alessandro; Maio Michele; Mazzaferro Vincenzo; Coppa Jorgelina; Srivastava Pramod K; Parmiani Giorgio
Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer.
Cancer immunology, immunotherapy : CII 2004;53(3):227-33.
2004: Lozupone Francesco; Pende Daniela; Burgio Vito Lelio; Castelli Chiara; Spada Massimo; Venditti Massimo; Luciani Francesca; Lugini Luana; Federici Cristina; Ramoni Carlo; Rivoltini Licia; Parmiani Giorgio; Belardelli Filippo; Rivera Paola; Marcenaro Stefania; Moretta Lorenzo; Fais Stefano
Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice.
Cancer research 2004;64(1):378-85.
2003: Parmiani Giorgio; Castelli Chiara; Rivoltini Licia; Casati Chiara; Tully Glenn A; Novellino Luisa; Patuzzo Andrea; Tosi Diego; Anichini Andrea; Santinami Mario
Immunotherapy of melanoma.
Seminars in cancer biology 2003;13(6):391-400.
2003: Lugini Luana; Lozupone Francesco; Matarrese Paola; Funaro Cristina; Luciani Francesca; Malorni Walter; Rivoltini Licia; Castelli Chiara; Tinari Antonella; Piris Adriano; Parmiani Giorgio; Fais Stefano
Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin.
Laboratory investigation; a journal of technical methods and pathology 2003;83(11):1555-67.
2003: Rodolfo Monica; Luksch Roberto; Stockert Elisabeth; Chen Yao-Tseng; Collini Paola; Ranzani Tiziana; Lombardo Claudia; Dalerba Piero; Rivoltini Licia; Arienti Flavio; Fossati-Bellani Franca; Old Lloyd J; Parmiani Giorgio; Castelli Chiara
Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Cancer research 2003;63(20):6948-55.
2003: Rivoltini Licia; Castelli Chiara; Carrabba Matteo; Mazzaferro Vincenzo; Pilla Lorenzo; Huber Veronica; Coppa Jorgelina; Gallino Gianfrancesco; Scheibenbogen Carmen; Squarcina Paola; Cova Agata; Camerini Roberto; Lewis Jonathan J; Srivastava Pramod K; Parmiani Giorgio
Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(7):3467-74.
2003: Di Nicola Massimo; Carlo-Stella Carmelo; Anichini Andrea; Mortarini Roberta; Guidetti Anna; Tragni Gabrina; Gallino Francesco; Del Vecchio Michele; Ravagnani Fernando; Morelli Daniele; Chaplin Paul; Arndtz Nathaly; Sutter Gerd; Drexler Ingo; Parmiani Giorgio; Cascinelli Natale; Gianni Alessandro M
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
Human gene therapy 2003;14(14):1347-60.
2003: Mazzaferro Vincenzo; Coppa Jorgelina; Carrabba Matteo G; Rivoltini Licia; Schiavo Marcello; Regalia Enrico; Mariani Luigi; Camerini Tiziana; Marchianò Alfonso; Andreola Salvatore; Camerini Roberto; Corsi Marco; Lewis Jonathan J; Srivastava Pramod K; Parmiani Giorgio
Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3235-45.
2003: Casati Chiara; Dalerba Piero; Rivoltini Licia; Gallino Gianfrancesco; Deho Paola; Rini Francesca; Belli Filiberto; Mezzanzanica Delia; Costa Aurora; Andreola Salvatore; Leo Ermanno; Parmiani Giorgio; Castelli Chiara
The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.
Cancer research 2003;63(15):4507-15.
2003: Maccalli Cristina; Pende Daniela; Castelli Chiara; Mingari Maria Cristina; Robbins Paul F; Parmiani Giorgio
NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
European journal of immunology 2003;33(7):2033-43.
2003: Parmiani G; Pilla L; Castelli C; Rivoltini L
Vaccination of patients with solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(6):817-24.
2003: Novellino Luisa; Renkvist Nicolina; Rini Francesca; Mazzocchi Arabella; Rivoltini Licia; Greco Angela; Deho Paola; Squarcina Paola; Robbins Paul F; Parmiani Giorgio; Castelli Chiara
Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(12):6363-70.
2003: Mortarini Roberta; Piris Adriano; Maurichi Andrea; Molla Alessandra; Bersani Ilaria; Bono Aldo; Bartoli Cesare; Santinami Mario; Lombardo Claudia; Ravagnani Fernando; Cascinelli Natale; Parmiani Giorgio; Anichini Andrea
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Cancer research 2003;63(10):2535-45.
2003: Dalerba Piero; Maccalli Cristina; Casati Chiara; Castelli Chiara; Parmiani Giorgio
Immunology and immunotherapy of colorectal cancer.
Critical reviews in oncology/hematology 2003;46(1):33-57.
2003: Carrabba Matteo G; Castelli Chiara; Maeurer Markus J; Squarcina Paola; Cova Agata; Pilla Lorenzo; Renkvist Nicolina; Parmiani Giorgio; Rivoltini Licia
Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
Cancer research 2003;63(7):1560-7.
2003: Lozupone Francesco; Rivoltini Licia; Luciani Francesca; Venditti Massimo; Lugini Luana; Cova Agata; Squarcina Paolo; Parmiani Giorgio; Belardelli Filippo; Fais Stefano
Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
European journal of immunology 2003;33(2):556-66.
2002: Rivoltini Licia; Carrabba Matteo; Huber Veronica; Castelli Chiara; Novellino Luisa; Dalerba Piero; Mortarini Roberta; Arancia Giuseppe; Anichini Andrea; Fais Stefano; Parmiani Giorgio
Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.
Immunological reviews 2002;188():97-113.
2002: Belli Filiberto; Testori Alessandro; Rivoltini Licia; Maio Michele; Andreola Giovanna; Sertoli Mario Roberto; Gallino Gianfrancesco; Piris Adriano; Cattelan Alessandro; Lazzari Ivano; Carrabba Matteo; Scita Giorgio; Santantonio Cristina; Pilla Lorenzo; Tragni Gabrina; Lombardo Claudia; Arienti Flavio; Marchianò Alfonso; Queirolo Paola; Bertolini Francesco; Cova Agata; Lamaj Elda; Ascani Lucio; Camerini Roberto; Corsi Marco; Cascinelli Natale; Lewis Jonathan J; Srivastava Pramod; Parmiani Giorgio
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(20):4169-80.
2002: Parmiani Giorgio; Sensi Marialuisa; Castelli Chiara; Rivoltini Licia; Anichini Andrea
T-cell response to unique and shared antigens and vaccination of cancer patients.
Cancer immunity : a journal of the Academy of Cancer Immunology 2002;2():6.
2002: Parmiani Giorgio; Castelli Chiara; Dalerba Piero; Mortarini Roberta; Rivoltini Licia; Marincola Francesco M; Anichini Andrea
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?
Journal of the National Cancer Institute 2002;94(11):805-18.
2002: Andreola Giovanna; Rivoltini Licia; Castelli Chiara; Huber Veronica; Perego Paola; Deho Paola; Squarcina Paola; Accornero Paola; Lozupone Francesco; Lugini Luana; Stringaro Annarita; Molinari Agnese; Arancia Giuseppe; Gentile Massimo; Parmiani Giorgio; Fais Stefano
Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles.
The Journal of experimental medicine 2002;195(10):1303-16.
2002: Sensi M; Pellegatta S; Vegetti C; Nicolini G; Parmiani G; Anichini A
Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones.
Tissue antigens 2002;59(4):273-9.
2002: Matarrese Paola; Di Biase Luigi; Santodonato Laura; Straface Elisabetta; Mecchia Monica; Ascione Barbara; Parmiani Giorgio; Belardelli Filippo; Ferrantini Maria; Malorni Walter
Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function.
The American journal of pathology 2002;160(4):1507-20.
2002: Carsana Marilisa; Tragni Gabrina; Nicolini Gabriella; Bersani Ilaria; Parmiani Giorgio; Anichini Andrea; Sun Yuan Sheng; Möller Peter; Schadendorf Dirk; Sensi Maria Luisa
Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine.
Cancer gene therapy 2002;9(3):243-53.
2002: Maio Michele; Fonsatti Ester; Lamaj Elda; Altomonte Maresa; Cattarossi Ilaria; Santantonio Cristina; Melani Cecilia; Belli Filiberto; Arienti Flavio; Colombo Mario P; Parmiani Giorgio
Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.
Cancer immunology, immunotherapy : CII 2002;51(1):9-14.
2001: Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot T J; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti M A
CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
British journal of cancer 2001;85(6):836-44.
2001: Rodolfo M; Catò E M; Soldati S; Ceruti R; Asioli M; Scanziani E; Vezzoni P; Parmiani G; Sacco M G
Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy.
Cancer gene therapy 2001;8(7):491-6.
2001: Mazzocchi A; Melani C; Rivoltini L; Castelli C; Del Vecchio M; Lombardo C; Colombo M P; Parmiani G
Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes.
Cancer immunology, immunotherapy : CII 2001;50(4):199-211.
2001: Renkvist N; Castelli C; Robbins P F; Parmiani G
A listing of human tumor antigens recognized by T cells.
Cancer immunology, immunotherapy : CII 2001;50(1):3-15.
2001: Castelli C; Ciupitu A M; Rini F; Rivoltini L; Mazzocchi A; Kiessling R; Parmiani G
Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.
Cancer research 2001;61(1):222-7.
2001: Parmiani G; Castelli C; Dalerba P; Rivoltini L
T cell response to tumor antigens and its therapeutic use in cancer patients.
Advances in experimental medicine and biology 2001;495():403-10.
2000: Bremers A J; Andreola S; Leo E; Gallino F; Rini F; Lombardo C; Belli F; Kuppen P J; Parmiani G; Castelli C
T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigens.
International journal of cancer. Journal international du cancer 2000;88(6):956-61.
2000: Parmiani G; Rivoltini L; Andreola G; Carrabba M
Cytokines in cancer therapy.
Immunology letters 2000;74(1):41-4.
2000: Lozupone F; Luciani F; Venditti M; Rivoltini L; Pupa S; Parmiani G; Belardelli F; Fais S
Murine granulocytes control human tumor growth in SCID mice.
International journal of cancer. Journal international du cancer 2000;87(4):569-73.
2000: Pisarra P; Lupetti R; Palumbo A; Napolitano A; Prota G; Parmiani G; Anichini A; Sensi M
Human melanocytes and melanomas express novel mRNA isoforms of the tyrosinase-related protein-2/DOPAchrome tautomerase gene: molecular and functional characterization.
The Journal of investigative dermatology 2000;115(1):48-56.
2000: Parmiani G; Rodolfo M; Melani C
Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal.
Human gene therapy 2000;11(9):1269-75.
2000: Bremers A J; Parmiani G
Immunology and immunotherapy of human cancer: present concepts and clinical developments.
Critical reviews in oncology/hematology 2000;34(1):1-25.
2000: Castelli C; Rivoltini L; Andreola G; Carrabba M; Renkvist N; Parmiani G
T-cell recognition of melanoma-associated antigens.
Journal of cellular physiology 2000;182(3):323-31.
2000: Mecchia M; Matarrese P; Malorni W; D'Agostino G; Sestili P; Santini S M; Gauzzi M C; Venditti M; Mazzocchi A; Parmiani G; Belardelli F; Ferrantini M
Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha.
Gene therapy 2000;7(2):167-79.
2000: Parmiani G
Immunological therapy of human tumors by gene-modified cellular vaccines.
Folia biologica 2000;46(6):207-9.
1999: Arienti F; Belli F; Napolitano F; Sulé-Suso J; Mazzocchi A; Gallino G F; Cattelan A; Santantonio C; Rivoltini L; Melani C; Colombo M P; Cascinelli N; Maio M; Parmiani G;
Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells.
Human gene therapy 1999;10(18):2907-16.
1999: Maccalli C; Pisarra P; Vegetti C; Sensi M; Parmiani G; Anichini A
Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(12):6912-23.
1999: Castellano M; Parmiani G
Genes involved in melanoma: an overview of INK4a and other loci.
Melanoma research 1999;9(5):421-32.
1999: Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni A M; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
The Journal of experimental medicine 1999;190(5):651-67.
1999: Rodolfo M; Zilocchi C; Cappetti B; Parmiani G; Melani C; Colombo M P
Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine.
Gene therapy 1999;6(5):865-72.
1999: Pisarra P; Mortarini R; Salvi S; Anichini A; Parmiani G; Sensi M
High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition.
Cancer immunology, immunotherapy : CII 1999;48(1):39-46.
1999: Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(3):1739-48.
1999: Rivoltini L; Squarcina P; Loftus D J; Castelli C; Tarsini P; Mazzocchi A; Rini F; Viggiano V; Belli F; Parmiani G
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.
Cancer research 1999;59(2):301-6.
1998: Di Nicola M; Siena S; Bregni M; Longoni P; Magni M; Milanesi M; Matteucci P; Mortarini R; Anichini A; Parmiani G; Drexler I; Erfle V; Sutter G; Gianni A M
Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.
Cancer gene therapy 1998;5(6):350-6.
1998: Wang Z; Arienti F; Parmiani G; Ferrone S
Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells.
European journal of immunology 1998;28(9):2817-26.
1998: Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo M P
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
Cancer research 1998;58(18):4146-54.
1998: Lupetti R; Pisarra P; Verrecchia A; Farina C; Nicolini G; Anichini A; Bordignon C; Sensi M; Parmiani G; Traversari C
Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage.
The Journal of experimental medicine 1998;188(6):1005-16.
1998: Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo M P; Parmiani G
Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(3):1220-30.
1998: Parmiani G
Future perspectives in specific immunotherapy of melanoma.
European journal of cancer (Oxford, England : 1990) 1998;34 Suppl 3():S42-7.
1998: Hicklin D J; Wang Z; Arienti F; Rivoltini L; Parmiani G; Ferrone S
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
The Journal of clinical investigation 1998;101(12):2720-9.
1998: Loftus D J; Squarcina P; Nielsen M B; Geisler C; Castelli C; Odum N; Appella E; Parmiani G; Rivoltini L
Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35).
Cancer research 1998;58(11):2433-9.
1998: Sensi M; Farina C; Maccalli C; Anichini A; Berd D; Parmiani G
Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(3):198-204.
1998: Clemente C; Rao S; Lupetti R; Tragni G; Pisarra P; Bersani I; Parmiani G; Mihm M C; Sensi M
Immunohistochemical analysis of the T-cell receptor beta-chain variable regions expressed by T lymphocytes infiltrating primary human melanoma.
Laboratory investigation; a journal of technical methods and pathology 1998;78(5):619-27.
1998: Castelli C; Mazzocchi A; Rini F; Tarsini P; Rivoltini L; Maio M; Gallino G; Belli F; Parmiani G
Immunogenicity of the ALLAVGATK (gp100[17-25]) peptide in HLA-A3.1 melanoma patients.
European journal of immunology 1998;28(4):1143-54.
1998: Bajetta E; Del Vecchio M; Mortarini R; Nadeau R; Rakhit A; Rimassa L; Fowst C; Borri A; Anichini A; Parmiani G
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):75-85.
1998: Belli F; Mascheroni L; Gallino G; Lenisa L; Arienti F; Melani C; Colombo M P; Parmiani G; Cascinelli N
Active immunization of metastatic melanoma patients with IL-2 or IL-4 gene transfected, allogeneic melanoma cells.
Advances in experimental medicine and biology 1998;451():543-5.
1998: Rivoltini L; Loftus D J; Squarcina P; Castelli C; Rini F; Arienti F; Belli F; Marincola F M; Geisler C; Borsatti A; Appella E; Parmiani G
Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.
Critical reviews in immunology 1998;18(1-2):55-63.
1997: Bertazzoli C; Marchesi E; Dermime S; Ravagnani F; Parmiani G; Gambacorti-Passerini C
HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins.
Tumori 1997;83(5):847-55.
1997: Ramakrishna V; Negri D R; Brusic V; Fontanelli R; Canevari S; Bolis G; Castelli C; Parmiani G
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells.
International journal of cancer. Journal international du cancer 1997;73(1):143-50.
1997: Parmiani G; Anichini A; Castelli C
New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses.
Melanoma research 1997;7 Suppl 2():S95-8.
1997: Belli F; Arienti F; Sulé-Suso J; Clemente C; Mascheroni L; Cattelan A; Santantonio C; Gallino G F; Melani C; Rao S; Colombo M P; Maio M; Cascinelli N; Parmiani G;
Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability.
Cancer immunology, immunotherapy : CII 1997;44(4):197-203.
1997: Maccalli C; Farina C; Sensi M; Parmiani G; Anichini A
TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(12):5902-13.
1997: Gambacorti-Passerini C; Bertazzoli C; Dermime S; Scardino A; Schendel D; Parmiani G
Mapping of HLA class I binding motifs in forty-four fusion proteins involved in human cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):675-83.
1997: Sensi M; Farina C; Maccalli C; Lupetti R; Nicolini G; Anichini A; Parmiani G; Berd D
Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.
The Journal of clinical investigation 1997;99(4):710-7.
1997: Castelli C; Rivoltini L; Mazzocchi A; Parmiani G
T-cell recognition of melanoma antigens and its therapeutic applications.
International journal of clinical & laboratory research 1997;27(2):103-10.
1997: Parmiani G; Colombo M P; Melani C; Arienti F
Cytokine gene transduction in the immunotherapy of cancer.
Advances in pharmacology (San Diego, Calif.) 1997;40():259-307.
1996: Arienti F; Sulé-Suso J; Belli F; Mascheroni L; Rivoltini L; Melani C; Maio M; Cascinelli N; Colombo M P; Parmiani G
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells.
Human gene therapy 1996;7(16):1955-63.
1996: Mazzocchi A; Storkus W J; Traversari C; Tarsini P; Maeurer M J; Rivoltini L; Vegetti C; Belli F; Anichini A; Parmiani G; Castelli C
Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(7):3030-8.
1996: Player M A; Barracchini K C; Simonis T B; Rivoltini L; Arienti F; Castelli C; Mazzocchi A; Belli F; Parmiani G; Marincola F M
Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(5):357-63.
1996: Farina C; van der Bruggen P; Boël P; Parmiani G; Sensi M
Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens.
International immunology 1996;8(9):1463-6.
1996: Caré A; Silvani A; Meccia E; Mattia G; Stoppacciaro A; Parmiani G; Peschle C; Colombo M P
HOXB7 constitutively activates basic fibroblast growth factor in melanomas.
Molecular and cellular biology 1996;16(9):4842-51.
1996: Loftus D J; Castelli C; Clay T M; Squarcina P; Marincola F M; Nishimura M I; Parmiani G; Appella E; Rivoltini L
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
The Journal of experimental medicine 1996;184(2):647-57.
1996: Rivoltini L; Loftus D J; Barracchini K; Arienti F; Mazzocchi A; Biddison W E; Salgaller M L; Appella E; Parmiani G; Marincola F M
Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(10):3882-91.
1996: Dermime S; Bertazzoli C; Marchesi E; Ravagnani F; Blaser K; Corneo G M; Pogliani E; Parmiani G; Gambacorti-Passerini C
Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):593-600.
1996: Vagliani M; Rodolfo M; Cavallo F; Parenza M; Melani C; Parmiani G; Forni G; Colombo M P
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells.
Cancer research 1996;56(3):467-70.
1996: Anichini A; Mortarini R; Maccalli C; Squarcina P; Fleischhauer K; Mascheroni L; Parmiani G
Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):208-17.
1996: Parmiani G; Arienti F; Sulé-Suso J; Melani C; Colombo M P; Ramakrishna V; Belli F; Mascheroni L; Rivoltini L; Cascinelli N
Cytokine-based gene therapy of human tumors. An overview.
Folia biologica 1996;42(6):305-9.
1995: Sensi M; Parmiani G
Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses.
Immunology today 1995;16(12):588-95.
1995: Melani C; Sulé-Suso J; Arienti F; MacCalli C; Passerini F; Colombo M P; Parmiani G
A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype.
Human gene therapy 1995;6(11):1427-36.
1995: Parmiani G; Colombo M P
Somatic gene therapy of human melanoma: preclinical studies and early clinical trials.
Melanoma research 1995;5(5):295-301.
1995: Sulé-Suso J; Arienti F; Melani C; Colombo M P; Parmiani G
A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes.
European journal of immunology 1995;25(10):2737-42.
1995: Melani C; Pupa S M; Stoppacciaro A; Ménard S; Colnaghi M I; Parmiani G; Colombo M P
An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines.
International journal of cancer. Journal international du cancer 1995;62(5):572-8.
1995: Salvi S; Segalla F; Rao S; Arienti F; Sartori M; Bratina G; Caronni E; Anichini A; Clemente C; Parmiani G
Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas.
Cancer research 1995;55(15):3374-9.
1995: Silvani A; Ferrari G; Paonessa G; Toniatti C; Parmiani G; Colombo M P
Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M.
Cancer research 1995;55(10):2200-5.
1995: Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo M P
CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
European journal of immunology 1995;25(1):137-46.
1995: Castelli C; Storkus W J; Maeurer M J; Martin D M; Huang E C; Pramanik B N; Nagabhushan T L; Parmiani G; Lotze M T
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes.
The Journal of experimental medicine 1995;181(1):363-8.
1994: Castelli C; Sensi M; Lupetti R; Mortarini R; Panceri P; Anichini A; Parmiani G
Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene.
Cancer research 1994;54(17):4785-90.
1994: Boiardi A; Silvani A; Ruffini P A; Rivoltini L; Parmiani G; Broggi G; Salmaggi A
Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.
Cancer immunology, immunotherapy : CII 1994;39(3):193-7.
1994: Arienti F; Sulé-Suso J; Melani C; Maccalli C; Belli F; Illeni M T; Anichini A; Cascinelli N; Colombo M P; Parmiani G
Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes.
Human gene therapy 1994;5(9):1139-50.
1994: Mazzocchi A; Belli F; Mascheroni L; Vegetti C; Parmiani G; Anichini A
Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients.
International journal of cancer. Journal international du cancer 1994;58(3):330-9.
1994: Silvani A; Salmaggi A; Parmiani G; Boiardi A
Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report.
Neurosurgery 1994;34(6):1078-80; discussion 1080-1.
1994: Rodolfo M; Castelli C; Bassi C; Accornero P; Sensi M; Parmiani G
Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors.
International journal of cancer. Journal international du cancer 1994;57(3):440-7.
1994: Maccalli C; Mortarini R; Parmiani G; Anichini A
Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles.
International journal of cancer. Journal international du cancer 1994;57(1):56-62.
1994: Melani C; Chiodoni C; Arienti F; Maccalli C; Sule-Suso J; Anichini A; Colombo M P; Parmiani G
Cytokine gene transduction in tumor cells: interleukin (IL)-2 or IL-4 gene transfer in human melanoma cells.
Natural immunity 1994;13(2-3):76-84.
1994: Mattei S; Colombo M P; Melani C; Silvani A; Parmiani G; Herlyn M
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes.
International journal of cancer. Journal international du cancer 1994;56(6):853-7.
1994: Lupetti R; Sensi M; Mortarini R; Anichini A; Clemente C; Parmiani G
N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma.
Melanoma research 1994;4(1):11-9.
1993: Parmiani G
Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells.
Immunology today 1993;14(11):536-8.
1993: Melani C; Silvani A; Parmiani G; Colombo M P
Lymphotoxin gene expression by melanocytes and melanoma cell lines and persistence of unspliced mRNA.
FEBS letters 1993;335(1):114-8.
1993: Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
The Journal of experimental medicine 1993;178(4):1231-46.
1993: Dermime S; Grignani F; Clerici M; Nervi C; Sozzi G; Talamo G P; Marchesi E; Formelli F; Parmiani G; Pelicci P G
Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the pml/RAR alpha protein.
Blood 1993;82(5):1573-7.
1993: Anichini A; Mortarini R; Parmiani G
The role of cytokines in the modulation of cell surface antigens of human melanoma.
The International journal of biological markers 1993;8(3):151-4.
1993: Stoppacciaro A; Melani C; Parenza M; Mastracchio A; Bassi C; Baroni C; Parmiani G; Colombo M P
Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma.
The Journal of experimental medicine 1993;178(1):151-61.
1993: Ruffini P A; Rivoltini L; Silvani A; Boiardi A; Parmiani G
Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.
Cancer immunology, immunotherapy : CII 1993;36(6):409-16.
1993: Melani C; Mattia G F; Silvani A; Carè A; Rivoltini L; Parmiani G; Colombo M P
Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes.
Blood 1993;81(10):2744-9.
1993: Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
The Journal of experimental medicine 1993;177(4):989-98.
1993: Rivoltini L; Viggiano V; Spinazzè S; Santoro A; Colombo M P; Takatsu K; Parmiani G
In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2. Role of interleukin 5.
International journal of cancer. Journal international du cancer 1993;54(1):8-15.
1993: Anichini A; Mortarini R; Alberti S; Mantovani A; Parmiani G
T-cell-receptor engagement and tumor ICAM-1 up-regulation are required to by-pass low susceptibility of melanoma cells to autologous CTL-mediated lysis.
International journal of cancer. Journal international du cancer 1993;53(6):994-1001.
1993: Gambacorti-Passerini C; Grignani F; Arienti F; Pandolfi P P; Pelicci P G; Parmiani G
Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.
Blood 1993;81(5):1369-75.
1993: Vagliani M; Melani C; Parmiani G; D'Eustachio P; Wettstein P J; Colombo M P
Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens. V. Chromosomal mapping of the immunodominant cytotoxic T-cell target-1 (CTT-1).
Immunogenetics 1993;38(2):157-60.
1992: Belli F; Arienti F; Rivoltini L; Santinami M; Mascheroni L; Prada A; Ammatuna M; Marchesi E; Parmiani G; Cascinelli N
Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
Melanoma research 1992;2(4):263-71.
1992: Sensi M; Castelli C; Salvi S; Mazzocchi A; Mortarini R; Nicolini G; Anichini A; Parmiani G
Expansion of major histocompatibility complex-restricted antimelanoma cytotoxic T-cell lymphocyte clones with identical T-cell receptor from tumor-infiltrating lymphocytes.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):207-11.
1992: Anichini A; Mortarini R; Parmiani G
Beta 1-integrins on melanoma clones regulate the interaction with autologous cytolytic T-cell clones.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(3):183-6.
1992: Colombo M P; Modesti A; Parmiani G; Forni G
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk.
Cancer research 1992;52(18):4853-7.
1992: Colombo M P; Maccalli C; Mattei S; Melani C; Radrizzani M; Parmiani G
Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines.
Melanoma research 1992;2(3):181-9.
1992: Mortarini R; Gismondi A; Santoni A; Parmiani G; Anichini A
Role of the alpha 5 beta 1 integrin receptor in the proliferative response of quiescent human melanoma cells to fibronectin.
Cancer research 1992;52(16):4499-506.
1992: Parmiani G; Anichini A; Carbone G; Sensi M
Can oncogene (RAS) activation predict susceptibility of human melanoma to activated lymphocytes and, therefore, the clinical response of such neoplasms to adoptive immunotherapy?
Melanoma research 1992;2(2):123-5.
1992: Rivoltini L; Cattoretti G; Arienti F; Mastroianni A; Parmiani G
CEA and NCA expressed by colon carcinoma cells affect their interaction with and lysability by activated lymphocytes.
The International journal of biological markers 1992;7(3):143-7.
1992: Colombo M P; Lombardi L; Stoppacciaro A; Melani C; Parenza M; Bottazzi B; Parmiani G
Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. Neutrophils discriminate between G-CSF-producing and G-CSF-nonproducing tumor cells.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(1):113-9.
1992: Sensi M; Bergomi M; Panceri P; Castelli C; Lupetti R; Traversari C; Carbone G; Parmiani G
Involvement of somatically acquired ecotropic viruses in the immunogenicity of nude-transplanted NIH/3T3 transformed cell lines.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(1):277-83.
1992: Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani E M; Corneo G; Parmiani G
Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(2):155-62.
1992: Colombo M P; Mattei S; Parmiani G
Cytokine gene transfer in tumor cells as an approach to antitumor therapy.
International journal of clinical & laboratory research 1992;21(4):278-82.
1992: Rivoltini L; Arienti F; Orazi A; Cefalo G; Gasparini M; Gambacorti-Passerini C; Fossati-Bellani F; Parmiani G
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype.
Cancer immunology, immunotherapy : CII 1992;34(4):241-51.
1991: Radrizzani M; Benedetti B; Castelli C; Longo A; Ferrara G B; Herlyn M; Parmiani G; Fossati G
Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional analysis of lymphocyte-melanoma interactions.
International journal of cancer. Journal international du cancer 1991;49(6):823-30.
1991: Sensi M; Castelli C; Anichini A; Grossberger D; Mazzocchi A; Mortarini R; Parmiani G
Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumour reactivity do not share the same TCR V alpha and V beta gene families.
Melanoma research 1991;1(4):261-71.
1991: Mazzocchi A; Rodolfo M; Parmiani G; Anichini A
An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis.
Melanoma research 1991;1(3):169-76.
1991: Melani C; Rivoltini L; Parmiani G; Calabretta B; Colombo M P
Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb.
Cancer research 1991;51(11):2897-901.
1991: Colombo M P; Ferrari G; Stoppacciaro A; Parenza M; Rodolfo M; Mavilio F; Parmiani G
Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo.
The Journal of experimental medicine 1991;173(4):889-97.
1991: Rivoltini L; Cattoretti G; Arienti F; Mastroianni A; Melani C; Colombo M P; Parmiani G
The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype.
International journal of cancer. Journal international du cancer 1991;47(5):746-54.
1991: Carbone G; Borrello M G; Molla A; Rizzetti M G; Pierotti M A; Della Porta G; Parmiani G
Activation of ras oncogenes and expression of tumor-specific transplantation antigens in methylcholanthrene-induced murine fibrosarcomas.
International journal of cancer. Journal international du cancer 1991;47(4):619-25.
1991: Mortarini R; Anichini A; Parmiani G
Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins.
International journal of cancer. Journal international du cancer 1991;47(4):551-9.
1991: Castelli C; Sensi M; Parmiani G
Recombinant interferon-gamma differently affects DQA and DRA gene expression in two human melanoma clones: transcriptional and posttranscriptional regulation.
Experimental and clinical immunogenetics 1991;8(1):38-48.
1991: Colombo M P; Ferrari G; Biondi G; Galasso D; Howe C C; Parmiani G
Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts.
European journal of cancer (Oxford, England : 1990) 1991;27(1):58-62.
1991: Rodolfo M; Salvi C; Bassi C; Rovetta G; Melani C; Colombo M P; Parmiani G
Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.
Natural immunity and cell growth regulation 1991;10(6):308-19.
1991: Rodolfo M; Bassi C; Salvi C; Parmiani G
Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours.
Cancer immunology, immunotherapy : CII 1991;34(1):53-62.
1990: Squadrelli-Saraceno M; Rivoltini L; Cantù G; Ravagnani F; Parmiani G; Molinari R
Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2.
Tumori 1990;76(6):566-71.
1990: Sensi M; Bergomi M; Formelli F; Parmiani G
Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity.
International journal of cancer. Journal international du cancer 1990;46(6):1088-94.
1990: Rivoltini L; Colombo M P; Supino R; Ballinari D; Tsuruo T; Parmiani G
Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line.
International journal of cancer. Journal international du cancer 1990;46(4):727-32.
1990: Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso M I; Cantù G; Molinari R; Orazi A; Parmiani G
In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Cancer research 1990;50(17):5551-7.
1990: Anichini A; Mortarini R; Supino R; Parmiani G
Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability.
International journal of cancer. Journal international du cancer 1990;46(3):508-15.
1990: Munari L; Silvani A; Passerini C G; Radrizzani M; Parmiani G; Boiardi A
Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
Journal of neurosurgical sciences 1990;34(3-4):283-8.
1990: Anichini A; Mortarini R; Berti E; Parmiani G
Multiple VLA antigens on a subset of melanoma clones.
Human immunology 1990;28(2):119-22.
1990: Parmiani G
An explanation of the variable clinical response to interleukin 2 and LAK cells.
Immunology today 1990;11(4):113-5.
1990: Parmiani G; Anichini A; Fossati G
Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?
Journal of the National Cancer Institute 1990;82(5):361-70.
1990: Mortarini R; Belli F; Parmiani G; Anichini A
Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations.
International journal of cancer. Journal international du cancer 1990;45(2):334-41.
1990: Castelli C; Mazzucchelli F; Sensi M; Carbone G; Parmiani G
H-2 class I gene analysis in 3-methylcholanthrene-induced murine fibrosarcomas.
Experimental and clinical immunogenetics 1990;7(2):129-35.
1990: Sensi M; Grazioli L; Rodolfo M; Parmiani G
Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors.
Cancer immunology, immunotherapy : CII 1990;31(1):37-43.
1990: Rodolfo M; Salvi C; Bassi C; Parmiani G
Adoptive immunotherapy of a mouse colon carcinoma with recombinant interleukin-2 alone or combined with lymphokine-activated killer cells or tumor-immune lymphocytes. Survival benefit of adjuvant post-surgical treatments and comparison with experimental metastases model.
Cancer immunology, immunotherapy : CII 1990;31(1):28-36.
1990: Mazzocchi A; Anichini A; Castelli C; Sensi M; Poli F; Russo C; Parmiani G
T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: evidence with a single T cell clone.
Cancer immunology, immunotherapy : CII 1990;32(1):13-21.
1990: Rodolfo M; Salvi C; Bassi C; Sensi M; Parmiani G
Adoptive immunotherapeutic treatments with interleukin 2 and lymphocytes in a mouse colonic adenocarcinoma model.
Annali dell'Istituto superiore di sanità 1990;26(3-4):423-32.
1989: Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka A R; Cascinelli N; Parmiani G
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
Cancer research 1989;49(18):5230-4.
1989: Colombo M P; Baracetti P; Cairo G; Schneider C; Parmiani G
A TaqI RFLP at the gas-2 locus.
Nucleic acids research 1989;17(18):7545.
1989: Castelli C; Mazzucchelli F; Sensi M; Fossati G; Parmiani G
Loss of heterozygosity of DQ alpha gene in human malignant melanoma.
Tumori 1989;75(4):378-82.
1989: Cascinelli N; Belli F; Marchini S; Marolda R; Prada A; Sciorelli G; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G
A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patients.
Tumori 1989;75(3):233-44.
1989: Rivoltini L; Gambacorti-Passerini C; Supino R; Parmiani G
Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance.
International journal of cancer. Journal international du cancer 1989;43(5):880-5.
1989: Anichini A; Mazzocchi A; Fossati G; Parmiani G
Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(10):3692-701.
1989: Traversari C; Carbone G; Della Torre G; Bergomi M; Parmiani G; Sensi M
Expression of retrovirus-related, cytotoxic T lymphocyte- and transplantation-defined antigens in NIH/3T3 transfectants after a single passage in nude mice.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(8):2887-94.
1989: Rodolfo M; Salvi C; Parmiani G
Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
Cancer immunology, immunotherapy : CII 1989;28(2):136-42.
1989: Parmiani G; Rivoltini L
In vitro lymphocyte response to autologous melanoma: clues in designing new adoptive immunotherapy protocols.
European journal of cancer & clinical oncology 1989;25 Suppl 3():S37-9.
1989: Colombo M P; Biondi G; Galasso D; Baracetti P; Howe C C; Parmiani G
Osteonectin transcript and metastatic behavior in v-Ki-ras transformed fibroblasts.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1989;4():76-7.
1989: Radrizzani M; Quaia M; Benedetti B; Andreola S; Vaglini M; Galligioni E; Fossati G; Parmiani G
Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.
Cancer immunology, immunotherapy : CII 1989;30(4):233-8.
1989: Radrizzani M; Gambacorti-Passerini C; Parmiani G; Fossati G
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.
Cancer immunology, immunotherapy : CII 1989;28(1):67-73.
1988: Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Supino R; Mariani M; Parmiani G
Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).
Cancer metastasis reviews 1988;7(4):335-45.
1988: Gambacorti-Passerini C; Radrizzani M; Rivoltini L; Marchesi E; Ravagnani F; Sciorelli G; Cascinelli N; Parmiani G
A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancer.
Tumori 1988;74(5):523-30.
1988: Gambacorti-Passerini C; Rivoltini L; Supino R; Mariani M; Parmiani G
Differential lysis of melanoma clones by autologous recombinant interleukin 2-activated lymphocytes. Relationship with spontaneous resistance to doxorubicin (Dx).
International journal of cancer. Journal international du cancer 1988;42(4):544-8.
1988: Colombo M P; Galasso D; Ferrari G; Parmiani G
Strain polymorphism and tentative mapping of mouse ornithine decarboxylase.
Nucleic acids research 1988;16(18):9075.
1988: Fossati G; Anichini A; Squarcina P; Mazzocchi A; Parmiani G
Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma.
International journal of cancer. Journal international du cancer 1988;42(2):239-45.
1988: Gambacorti-Passerini C; Radrizzani M; Marolda R; Belli F; Sciorelli G; Galazka A R; Schindler J D; Cascinelli N; Parmiani G
In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2.
International journal of cancer. Journal international du cancer 1988;41(5):700-6.
1988: Gambacorti-Passerini C; Rivoltini L; Supino R; Rodolfo M; Radrizzani M; Fossati G; Parmiani G
Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
Cancer research 1988;48(9):2372-6.
1988: Anichini A; Castelli C; Sozzi G; Fossati G; Parmiani G
Differential susceptibility to recombinant interferon-gamma-induced HLA-DQ antigen modulation among clones from a human metastatic melanoma.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(1):183-91.
1988: Taramelli D; Mazzocchi A; Clemente C; Fossati G; Parmiani G
Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes.
Cancer immunology, immunotherapy : CII 1988;26(1):61-6.
1988: Fossati G; Anichini A; Mazzocchi A; Squarcina P; Parmiani G
Reactivity of human lymphocyte clones to autologous metastatic melanoma cells.
Advances in experimental medicine and biology 1988;233():73-80.
1988: Parmiani G; Fossati G; Radrizzani M; Gambacorti-Passerini C; Marolda R; Cascinelli N
Potential therapeutic use of autologous human lymphocytes in metastatic melanoma: in vivo interleukin 2-activated peripheral blood lymphocytes and in vitro activated peripheral blood and tumor-infiltrating lymphocytes.
Advances in experimental medicine and biology 1988;233():453-8.
1988: Rodolfo M; Balsari A; Clemente C; Parmiani G; Fossati G
Tumorigenicity and dissemination of primary and metastatic human melanomas implanted into different sites in athymic nude mice.
Invasion & metastasis 1988;8(6):317-31.
1987: Marolda R; Belli F; Prada A; Villani F; Gambacorti-Passerini C; Galazka A; Parmiani G; Cascinelli N
A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects.
Tumori 1987;73(6):575-84.
1987: Parmiani G; Grazioli L; Sensi M; Colombo M P; Rodolfo M
Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes.
Biochimica et biophysica acta 1987;907(2):163-74.
1987: Gambacorti-Passerini C; Radrizzani M; Erba E; Fossati G; Parmiani G
Lysis by activated lymphocytes of melanoma and small cell lung cancer cells surviving in vitro treatment with mafosfamide.
Cancer research 1987;47(10):2547-52.
1987: Traversari C; Ferrari G; Grazioli L; Ballinari D; Colombo M P; Castelli C; Pierotti M A; Parmiani G
Ly-5.185 molecule is associated with thymic maturation of lymphocytes but not with their cytotoxic activity.
Experimental and clinical immunogenetics 1987;4(2):106-14.
1987: Grazioli L; Sensi M; Parmiani G
Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma.
Cancer immunology, immunotherapy : CII 1987;24(3):237-43.
1986: Balsari A; Tona G; Colombo M P; Fossati G; Parmiani G
Control of human melanoma growth in nude mice by autologous allo-activated peripheral blood lymphocytes.
International journal of cancer. Journal international du cancer 1986;38(6):923-7.
1986: Fossati G; Anichini A; Taramelli D; Balsari A; Gambacorti-Passerini C; Kirkwood J M; Parmiani G
Immune response to autologous human melanoma: implication of class I and II MHC products.
Biochimica et biophysica acta 1986;865(3):235-51.
1986: Gambacorti-Passerini C; Marolda R; Tona G; Sciorelli G; Fossati G; Cascinelli N; Parmiani G
Infusion of autologous alloactivated lymphocytes in melanoma patients: toxicity and immunologic monitoring.
Tumori 1986;72(4):383-8.
1986: Parmiani G; Taramelli D; Anichini A; Andreola S; Cascinelli N; Fossati G
Phenotypic heterogeneity of HLA products on human melanoma cells.
Journal of immunogenetics 1986;13(2-3):235-40.
1986: Parmiani G; Sensi M L; Balsari A; Colombo M P; Gambacorti-Passerini C; Grazioli L; Rodolfo M; Cascinelli N; Fossati G
Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studies.
La Ricerca in clinica e in laboratorio 1986;16(1):1-20.
1986: Sensi M; Grazioli L; Parmiani G
Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells.
Cancer immunology, immunotherapy : CII 1986;21(3):199-204.
1986: Balsari A; Marolda R; Gambacorti-Passerini C; Sciorelli G; Tona G; Cosulich E; Taramelli D; Fossati G; Parmiani G; Cascinelli N
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study.
Cancer immunology, immunotherapy : CII 1986;21(2):148-55.
1985: Ballinari D; Grazioli L; Sensi M L; Borrello M G; Parmiani G
DBA/2-like minor histocompatibility antigens on a BALB/c lymphoma. A BALB/c anti-DBA/2 serum which lyses the tumor and blocks BALB/c anti-tumor and anti-DBA/2 effectors.
International journal of cancer. Journal international du cancer 1985;36(5):617-22.
1985: Carbone G; Pierotti M A; Boiocchi M; De Leo A B; Ballinari D; Radice P; Borrello M G; Meseguer A; Cernuschi A; Parmiani G
Cell surface antigens of chemically induced fibrosarcomas: detection by a monoclonal antibody of a tumor-restricted Mr 12,000 protein gag antigen encoded by a dual-tropic murine leukemia virus.
Cancer research 1985;45(10):4980-5.
1985: Ballinari D; Castelli C; Traversari C; Pierotti M A; Parmiani G; Palmieri G; Ricciardi-Castagnoli P; Adorini L
Disulfide-linked surface molecules of monoclonal antigen-specific suppressor T cells: evidence for T cell receptor structures.
European journal of immunology 1985;15(8):855-60.
1985: Balsari A; Fossati G; Taramelli D; Tona G; Delia D; Giardini R; Parmiani G
Allostimulation of patients' lymphocytes generates both T and NK-like cells cytotoxic for autologous melanoma.
British journal of cancer 1985;52(1):73-80.
1985: Parmiani G; Fossati G; Taramelli D; Anichini A; Balsari A; Gambacorti-Passerini C; Sciorelli G; Cascinelli N
Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.
Cancer metastasis reviews 1985;4(1):7-26.
1984: Taramelli D; Fossati G; Balsari A; Marolda R; Parmiani G
The inhibition of lymphocyte stimulation by autologous human metastatic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells.
International journal of cancer. Journal international du cancer 1984;34(6):797-806.
1984: Fossati G; Taramelli D; Balsari A; Bogdanovich G; Andreola S; Parmiani G
Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes.
International journal of cancer. Journal international du cancer 1984;33(5):591-7.
1984: Balsari A; Fossati G; Taramelli D; Nava M; Ravagnani F; Parmiani G
Inhibition of human melanoma growth in nude mice by autologous, alloactivated peripheral blood lymphocytes.
Tumori 1984;70(1):35-9.
1984: Pierotti M A; Traversari C; Ballinari D; Borrello M G; Parmiani G
Ly-5 molecular forms in congenitally immunodeficient mice.
Experimental and clinical immunogenetics 1984;1(2):75-82.
1983: Pierotti M A; Ballinari D; Colombo M P; Grazioli L; Parmiani G
Role of the carbohydrate prosthetic groups in the biosynthesis of membrane antigens and in the H-2-restricted lysis of MBL-2 lymphoma cells.
Transplantation proceedings 1983;15(4):2068-73.
1983: Ballinari D; Pierotti M A; Sensi M L; Parmiani G
Lack of H-2Ld locus products on a BALB/c fibrosarcoma expressing H-2k-like alien antigens.
Journal of immunogenetics 1983;10(2):115-25.
1983: Carbone G; Colombo M P; Sensi M L; Cernuschi A; Parmiani G
In vitro detection of cell-mediated immunity to individual tumor-specific antigens of chemically induced BALB/c fibrosarcomas.
International journal of cancer. Journal international du cancer 1983;31(4):483-9.
1982: Ballinari D; Pierotti M A; Grazioli L; Cattaneo M; Rogers M J; Parmiani G
Biochemical analysis of a public H-2 specificity revealed by an anomalous reaction of an alloantiserum with a chemically induced C57BL/10 fibrosarcoma.
Journal of immunogenetics 1982;9(4):267-75.
1982: Parmiani G; Sensi M L; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J
Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
International journal of cancer. Journal international du cancer 1982;29(3):323-32.
1982: Fossati G; Balsari A; Taramelli D; Sensi M L; Pellegris G; Nava M; Parmiani G
Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes.
Cancer immunology, immunotherapy : CII 1982;14(2):99-104.
1981: Rogers M J; Carbone G; Ballinari D; Cattaneo M; Parmiani G
Biochemical characterization of the anomalous reaction of anti-H-2b alloantiserum with a chemically induced sarcoma of H-2k origin.
Transplantation proceedings 1981;13(4):1774-81.
1980: Parmiani G; Ballinari D; Sensi M L
Tumor-associated alien alloantigens of BALB/c tumors encoded by the MHC and by non-H-2 genes: a histogenetic study.
Journal of immunology (Baltimore, Md. : 1950) 1980;124(2):662-8.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Giorgio Parmiani

Research Profile (preview)

Disorders

Chemicals & Drugs

Physiology

Anatomy

Living Beings

Procedures

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Giorgio Parmiani (preview)

All Publications